Evaluation of gas chromatography mass spectrometry and pattern recognition for the identification of bladder cancer from urine headspace by Cauchi, M et al.
Open Research Online
The Open University’s repository of research publications
and other research outputs
Evaluation of gas chromatography mass spectrometry
and pattern recognition for the identification of bladder
cancer from urine headspace
Journal Item
How to cite:
Cauchi, M; Weber, C. M.; Bolt, B. J.; Spratt, P. B.; Bessant, C.; Turner, D. C.; Willis, C. M.; Britton, L.
E.; Turner, C. and Morgan, G. (2016). Evaluation of gas chromatography mass spectrometry and pattern recognition
for the identification of bladder cancer from urine headspace. Analytical Methods, 8(20) pp. 4037–4046.
For guidance on citations see FAQs.
c© 2016 The Royal Society of Chemistry
Version: Version of Record
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1039/c6ay00400h
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Evaluation of gas chromatography mass
spectrometry and pattern recognition for the
identiﬁcation of bladder cancer from urine
headspace
M. Cauchi,*a C. M. Weber,a B. J. Bolt,a P. B. Spratt,a C. Bessant,b D. C. Turner,c
C. M. Willis,d L. E. Britton,d C. Turnerc and G. Morganc
Previous studies have indicated that volatile organic compounds speciﬁc to bladder cancer may exist in
urine headspace, raising the possibility that they may be of diagnostic value for this particular cancer. To
further examine this hypothesis, urine samples were collected from patients diagnosed with either
bladder cancer or a non-cancerous urological disease/infection, and from healthy volunteers, from
which the volatile metabolomes were analysed using gas chromatography mass spectrometry. The
acquired data were subjected to a speciﬁcally designed pattern recognition algorithm, involving cross-
model validation. The best diagnostic performance, achieved with independent test data provided by
healthy volunteers and bladder cancer patients, was 89% overall accuracy (90% sensitivity and 88%
speciﬁcity). Permutation tests showed that these were statistically signiﬁcant, providing further evidence
of the potential for volatile biomarkers to form the basis of a non-invasive diagnostic technique.
Introduction
Bladder cancer is the seventh most common cancer in the UK,
with over 10 700 new cases diagnosed in 2012.1 As with most
cancers, early diagnosis greatly increases the chances of
survival; individuals presenting with stage I tumours having
a one year relative survival rate of around 97%, compared to
26% for those with stage IV disease.2 For people exhibiting
symptoms or requiring surveillance, cystoscopy with biopsy
remains the “gold standard” investigative technique for bladder
cancer detection, but is invasive, expensive and time-
consuming. Urine cytology can be a useful non-invasive adjunct
to diagnosis, since it has a high specicity for bladder cancer
(96–98%), but its sensitivity is low (22–52%), especially for low-
grade tumours which shed proportionally fewer cells into the
urine. Furthermore, an experienced cytologist or pathologist is
needed to perform the cytological evaluation, making the test
relatively expensive and slow.3
Utilisation of molecular biomarkers present in urine oﬀers
a promising alternative non-invasive approach to diagnosis,
which if suﬃciently accurate, rapid and cheap has the potential
to be used for mass screening of the population. Of the protein
markers which have so far been investigated in depth, three
have achieved FDA approval as assays for diagnosis and/or
follow-up – nuclear mitotic apparatus protein (NMP22),
complement factor H-related protein and complement factor H
(BTA stat® and BTA TRAK®), and carcinoembryonic antigen
combined with two bladder tumour cell-associated mucins
(ImmunoCyt™/uCyt+™).4,5 Whilst these are more sensitive
than urine cytology, having reported sensitivities of 47–100%,
53–83% and 50–100%, respectively, specicities are signi-
cantly lower at 60–90%, 51–75% and 69–79%, respectively.
Recently, it has been suggested that volatile organic
compounds (VOCs) present in the headspace of urine from
bladder cancer suﬀerers may be used as diagnostic biomarkers.
This concept was initially demonstrated in a canine olfactory
proof-of-principle study by Willis et al.6 and subsequently sup-
ported by ndings using a metal oxide semiconductor (MOS)
and eld eﬀect transistor (MOSFET) gas sensor array,7 where
sensitivity and specicity rates of up to 70% were achieved. A
more recent pilot study by Khalid et al.8 involving 24 bladder
cancer patients and 74 control patients with non-malignant
urological disease, utilised an in-house fabricated combined
gas chromatography (GC) MOS-sensor device with pattern
recognition, reporting accuracies of between 93% and 100% for
the correct assignment of urine samples. Although very prom-
ising, the authors acknowledge that larger sample sizes are
needed to conrm the results.
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Gas sensor arrays undoubtedly oﬀer practical advantages
over trained dogs for the detection of the urinary VOCs associ-
ated with bladder cancer. However, they currently exhibit
performance limitations, including sensor dri and a lack of
inter-device reproducibility, and, furthermore, cannot be used
to identify the chemical nature of individual volatile
biomarkers. In the present study, we apply a more revealing
analytical technique; that of gas chromatography mass spec-
trometry (GC-MS), and further demonstrates the potential for
VOCs as a diagnostic approach to bladder cancer. GC-MS has
already shown promise in the early diagnosis of lung cancer
based on the analysis of VOCs contained in breath samples.9 It
is now an important analytical technique in the eld of
metabolomics due to its high sensitivity, reproducibility and
peak resolution.10 As early as 1980, methods had been estab-
lished that could identify up to 155 metabolites in samples
originating from urine.11,12
A number of diﬀerent mass spectrometry systems are avail-
able for such analysis, including time-of-ight (ToF) and
quadrupoles coupled with a database containing a library of
spectral data for the identication of compounds.13 Recent
advances have been seen in the separation of compounds with
the advent of GCx-GC coupled with ToF-MS.14 In this regard,
copious amounts of data are generated which require a robust
statistical analytical approach, such as chemometrics,15 and, in
particular, multivariate data analysis. This can sometimes
involve an exploratory approach typically using principal
components analysis (PCA) to identify possible trends and
outlying samples16 which is followed by pattern recognition.17
The latter, in the form of multivariate classication with partial
least squares discriminant analysis (PLS-DA), can deduce which
type of class a particular sample belongs to, for example,
healthy or diseased.18,19 Although there are other machine
learning algorithms available, e.g. articial neural networks
(ANNs),20 random forests21 and support vector machines
(SVMs),22,23 PLS-DA permits visualisation of the most signicant
features in a given chromatogram via the PLS loadings.19,24
This paper presents the identication and classication of
bladder cancer via the multivariate statistical technique of
partial least squares discriminant analysis (PLS-DA) and the
machine learning approaches of support vector machines and
random forests, on GC-MS data acquired from urine samples.
Experimental
Reagents
Analytical grade reagents and solvents were employed, unless
otherwise stated.
Participant selection
A total of 72 patients (Table 1) presenting at Buckinghamshire
Healthcare NHS Trust with new or recurrent transitional cell
carcinoma (TCC) of the bladder donated urine prior to surgical
intervention. Grade and stage of the tumour were recorded, and
three groups drawn up based on grade: TCC1 – low grade or well
diﬀerentiated; TCC2 – moderately diﬀerentiated; TCC3 – high
grade or poorly diﬀerentiated. An additional 205 control
subjects, categorised into one of three groups (controls 1, 2 and
3, depending upon age and disease status), also provided urine
samples. The control groups were split as follows: control group
1 (C1) – no urine abnormality on dipstick analysis; Control
group 2 (C2) – any non-urological non-cancerous condition or
disease, and/or one or more positive dipstick ndings of
a minor nature. Menstruating women with blood in their urine
were included in this group, for example, as were individuals
with suspected urinary tract infection, positive for leucocytes,
blood and/or protein.
Control group 3 (C3) – conrmed non-cancerous urological
disease, with or without urine dipstick abnormalities. Urolog-
ical conditions included renal and ureteric stones, renal cysts
and polypoid cystitis.
As criteria for inclusion/exclusion, controls over 32 years of
age were required to have had recent cystoscopy to exclude
visible bladder malignancy. For both controls and the cancer
positive group (TCC), men over 50 years were only included if
recent cancer-negative prostate histology had been demon-
strated. Individuals with pre-malignant urological disease or
a history of urological carcinoma other than TCC were excluded.
A history of malignancy in other organ systems (>5 years
previously) was acceptable, providing the individual was now
considered disease-free. All other past and/or present medical
conditions were permissible. There were no exclusions on the
basis of medication, menstrual cycle, diet, alcohol consump-
tion, or chemical exposure. However, details of all of these
factors were recorded for each participant, should their inu-
ence on the composition and odour of the urine need to be
considered at any stage. Special attention was paid to smoking
habits, with 28% of those with bladder cancer being current
cigarette smokers, as compared to 31% control subjects. Finally,
in order to ensure that age would not be a main contributory
factor when comparing the C3 group against the TCC groups, 18
subjects under the age of 50 were omitted from the C3 group.
The study was given favourable ethical opinion by the Mid
and South Buckinghamshire Local Research Ethics Committee
(04/Q1607/65), and all participants gave written informed
consent; aer samples were taken, they and all subsequent data
were anonymised.
Analysis and processing of urine samples
Following urinalysis (Multistix 10 SG, Bayer Corporation, NY,
USA), fresh urine specimens were refrigerated immediately, and
frozen as soon as possible as 0.5 ml aliquots in glass vials. The
median time interval between refrigeration and freezing was 3
hours (range 1–24 hours). Samples were then stored at 80 C
until required. It was found in a recent study that the eﬀect of
freezing samples had no noticeable eﬀect on the volatile
composition of the samples.25 The use of glass vials has recently
become of concern due to it being able to absorb volatiles.26
However the absorption of analytes onto the glass is dependent
on a very large range of factors including concentration, func-
tional groups, etc. Generally, freezing reduces the likelihood of
interaction with the glass vials. Though reduced surface activity
4038 | Anal. Methods, 2016, 8, 4037–4046 This journal is © The Royal Society of Chemistry 2016
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(RSA) vials are readily available which signicantly reduces
silanols and surface ions on the glass surface,27 they were not
available during the initial stages of the work and thus glass
vials were employed. However, it is stressed that the smallest
glass vials were utilised to minimise the headspace and the
surface area therefore resulting in minimal losses. Incidentally,
plastic vials would not be suitable for GC analyses.
Headspace analysis
Gas chromatography mass spectrometry was used to charac-
terise the VOC (volatile organic compound) content of urine.
Measurements were performed using the following
instrumentation:
 CTC CombiPal Autosampler (CTC Analytics, Switzerland):
to automatically introduce the sample into the inlet.
 Agilent 6890 GC with S/SL inlet (Agilent Technologies, CA,
USA): a gas chromatograph with an injector to introduce the
vaporised sample onto the column.
 Leco Pegasus 4D ToFMS (Leco Corp., MI, USA): a time of
ight mass spectrometer.
A total of 832 urine (C1, C2, C3, TCC1, TCC2 and TCC3)
samples were randomly analysed over 9 batches and inter-
spersed with either a bre blank (no sample) or sample blank
(urine replaced with 0.5 ml deionised water) aer every 5
injections. All samples were prepared by placing a 0.5 ml
sample in a pre-conditioned 10ml headspace vial containing 1 g
anhydrous sodium sulphate (Fisher Scientic UK Ltd., Lough-
borough, UK) conditioned overnight at 100 C and 1.5 ml of 0.1
M hydrochloric acid (Fisher Scientic UK Ltd., Loughborough,
UK). An internal standard in the form of deuterated (d6-) phenol
(ISOTEC, Miamisburg, Ohio, USA) at a concentration of 100 mg
ml1 was spiked (10 ml) into the vial which was immediately
capped. This mixture was pre-equilibrated for 10 minutes at 60
C. A pre-conditioned 75 mm carboxen/PDMS ber (Sigma-
Aldrich, Dorset, UK) was inserted for 5 minutes to extract the
volatile organic compounds and then the ber was exposed in
the GC inlet at 280 C for 2 minutes under splitless conditions
to desorb the analytes onto the column. In this work, only one
column was employed in the GC-ToF-MS instrument. The ana-
lytes were thus separated on a BP624 30 m  0.25 mm internal
diameter with a 1.4 mm lm thickness column (SGE Analytical
Science, Victoria, Australia) with the oven programmed from 30
C (2 minute hold) to 240 C at 20 C min1 (hold 1.5 min). The
data were collected at 10 spectra per second across the mass
range 33–350 m/z. The mass range started at m/z 33 so as to
avoid background interferences and higher baselines from the
oxygen (m/z 32) and nitrogen (m/z 28) and using this headspace
technique in order that analytes with amolecular weight greater
than 350 amu would not be introduced into the GC. The
reproducibility of the method was checked before measure-
ments of the samples were made in triplicate.
Finally, the data were stored in NetCDF format (Network
Common Data Form). These are binary les (i.e. cannot be
opened in a standard text editor, such as NotePad) in which
specic information is stored and all zero values are removed in
order to minimise the storage space used on a hard drive. All
information is stored as row vectors. Information includes
some of the following:
 Total_intensity: the sum of the abundances across all of the
retention times. The length of the vector is the number of
retention time scans.
 Scan_acquisition_time: the vector of retention time values
containing the time values in minutes.
 Scan_index: the index values indicating the starting posi-
tions of each retention time scan in the mass_values and
intensity_values vectors (see below). The length of the vector is
the number of retention time scans.
 Point_index: this gives the number of non-zero data points
for each retention time value. The length of the vector is the
number of retention time scans.
 Mass_values: the actual mass-to-charge (m/z) values corre-
sponding to the non-zero values. The length of the vector is the
sum of all the numerical values in the point_index vector.
 Intensity_values: the corresponding intensity values for
each of the respective mass values. The length of the vector is
the sum of all the numerical values in the point_index vector.
Data analysis
The provided NetCDF data les were processed and analysed
using MATLAB (R2011a, MathWorks Inc, USA). Each le con-
tained the information of the full spectral information of one
sample, a chromatogram, which was stored in a data matrix of
size m/z_values  scans. From a data storage point of view, all
samples build a cube – one chromatogram arranged behind the
other. Every single entry of the data matrix of one sample
represents the abundance of a specic ion at a certain point of
time. Each column in the matrix can be interpreted as a mass
spectrum. A typical mass spectrum is usually represented as
a “stick diagram”, displaying the relative current induced by
ions of alternating mass-to-charge ratio. But when it comes to
Table 1 Baseline characteristics of the subjects within each transitional cell carcinoma of the bladder (TCC) and control (C) group (N ¼ 259)
Group No. of subjects No. of males No. of females Age range (y) Median age (y)
TCC1 17 12 5 59–82 74.0
TCC2 28 19 9 50–86 66.5
TCC3 27 15 12 56–88 75.5
C1 70 29 41 18–31 26.0
C2 71 35 36 18–32 25.0
C3 46 8 38 50–89 66.0
This journal is © The Royal Society of Chemistry 2016 Anal. Methods, 2016, 8, 4037–4046 | 4039
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the storage of the data and the computational data processing
point of view, each mass spectrum is represented as an array of
numbers. The rows of a GC-MS chromatogram represent single
ion count (SIC) chromatograms. This fact allows inferring the
total ion count (TIC) chromatogram by summing up the
columns. This data reduction was necessary, as the majority of
multivariate data analysis techniques require two-dimensional
data.
For each NetCDF data le that was imported into the MAT-
LAB environment, and based on the knowledge of the contents
of the NetCDF le given previously, the GC-MS data matrix was
reconstructed to the order of m/z_values  scans re-inserting
zero values where appropriate into the single ion count (SIC)
chromatograms. All of the abundance values were normalised
against the abundance values of the deuterated (d6-) phenol
internal standard (atm/z 99). Them/z values are summed so that
a row vector is generated whose length is the number of scans
(i.e. the retention time values). The same process is repeated
with the remaining NetCDF les. Finally, all row vectors are
combined into a data matrix of the order samples  scans. Fig. 1
illustrates the relationship among the elements within a single
data matrix and demonstrates the formation of the dataset
containing the TIC of each sample.
As the process required chromatograms to be warped in time
to align corresponding peaks, correlation optimised warping
(COW) was applied28,29 on these data prior to further data
analysis. The “retention time shis” can be caused by physical
changes in the column, mobile phase composition, instru-
mental dri and interaction between analytes, and these must
be corrected.30 Although other warping methods exist,31–34 COW
was employed due to the ability to preserve peak shape and
area, in addition to the ability to deduce the optimal parameters
required for alignment of the retention time peaks.29 The
deduced optimal parameters are the segment (the number of
data points per interval) and the slack (the extent of warping/
shiing of the peaks in any direction). The segment and slack
values attained for C1 v TCC, C2 v TCC, C3 v TCC, C3 v TCC1, C3
v TCC2, and C3 v TCC3 were {31, 1}, {23, 1}, {6, 1}, {23, 1}, {19, 1}
and {6, 1} respectively.
Exploratory data analysis was accomplished via principal
components analysis (PCA) and hierarchical cluster analysis
(HCA), which are the most widely used multivariate statistical
techniques.15,35 This was performed to reveal natural groupings
based on the chromatograms of the GC-MS via the character-
istics that cause the greatest variance in the dataset.
Next, three pattern recognition tools were employed via
custom-written scripts to build classication models using the
cancer status of the samples: partial least squares discriminant
analysis (PLS-DA), random forests (RFs) and support vector
machines (SVMs). For PLS-DA, the PLS Toolbox 3.5 (Eigenvector
Research Inc., USA) was employed in MATLAB R2011a (Math-
Works Inc., Nattick, USA); for SVMs the libsvm3.20 toolbox was
employed; for RFs, MATLAB wasmade to call the RandomForest
package in R (3.0.2). All three techniques call for information
about the parameter of interest (the cancer status) to be known
in order to train the algorithm to identify those molecules that
diﬀerentiate between the classes.
PLS-DA is considered to be a dimensionality reduction
method and can be seen as the regression extension of principal
components analysis.36 Unlike PCA, which attempts to describe
the maximum variation in the measured data, PLS-DA tends to
maximise the covariance between the input data and the output
class. The information returned by PCA is that which was
caused by the attribute with the biggest variance. In contrast,
PLS-DA returns only data that were caused by the property
under investigation.
It is known that PLS-DA is prone to overestimate the accuracy
of classication if it is not accurately validated.37 For this reason
the number of latent variables (LVs) was varied from 1 to 20 in
each test run. Furthermore a very thorough evaluation process –
bootstrapping with optimisation by leave-one-out cross-valida-
tion (LOOCV)38,39 – was implemented to assess the performance
of the PLS-DA classier. In each bootstrap evaluation, the
dataset was randomly split into two subsets: the rst subset was
the bootstrap training set which would be used to determine the
optimum model parameters via LOO-CV and was made up of
70% of the original dataset; the remaining 30% formed the
bootstrap testing set which would be used to evaluate the model
at the determined optimum LV. This whole process was
repeated for the next bootstrap evaluation until all 150 evalua-
tions had taken place. A set of statistical parameters are then
calculated such as the overall accuracy, specicity, sensitivity
and the area under the receiver operating characteristic
(AUROC) curve which uses the trapezoid rule.40 This method
ensures that validation is sequentially performed on each
sample using a model that excludes the data from that sample.
Two machine learning algorithms were also employed:
random forests21 and support vector machines.23 In order to
ensure the optimum number of trees was employed for random
forests, they were varied from 50 up to 450 in steps of 100. The
linear kernel was employed for SVM. During the optimisation
process of the linear kernel the cost values applied were 0.5, 1.0,
2.0, 4.0 and 8.0. These two machine learning approaches were
Fig. 1 Storage of the full spectral information of one GC-MS data
sample. Each column of the data matrix represents a single mass
spectrum. Every row can be seen as a single ion count (SIC) chro-
matogram. Therefore the sum of all columns results in the total ion
count (TIC) chromatogram.
4040 | Anal. Methods, 2016, 8, 4037–4046 This journal is © The Royal Society of Chemistry 2016
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integrated into the bootstrapping procedures described in the
previous paragraph.
As nal validation of the results, and to attain an indication
of the statistical signicance of the results, permutation testing
involving a Monte Carlo simulation was used to evaluate the
obtained results.38 This involved repeated random sampling. In
this context a null model was generated from a set of data that
was statistically similar to the data under study, but for which it
was not expected to be able to build a meaningful classication
model. For each of the 6 datasets (C1 v TCC, C2 v TCC, C3 v TCC,
C3 v TCC1, C3 v TCC2, and C3 v TCC3), random class assigna-
tions were made to the samples in the datasets 300 times.
Within each random assignation, the datasets were subjected to
the bootstrap procedure described previously. For a disease
discriminating model trained on the real sample classes to be
considered statistically signicant it needs to achieve a classi-
cation accuracy towards the extremities of those produced by
the null models.
Results and discussion
Exploratory analysis via PCA and HCA
The visual outputs of the two independent exploratory tech-
niques of principal components analysis (PCA) and hierarchical
cluster analysis (HCA) did not disclose any separation by cancer
status of the samples, in any of the experiments. Other inu-
ences such as age, diet or gender may be responsible for the
groupings obtained. However, this does not mean that the data
do not contain any information concerning bladder cancer. The
PCA was able to demonstrate that the cancer status was not
responsible for the bigger part of the variance, captured by the
rst two or three principal components (PCs). Nevertheless,
investigating principal components of lower variance did not
lead to an explicitly disease-related diﬀerentiation, either.
Pattern recognition via PLS-DA, SVMs and RFs
Table 2 compares the results attained via the machine learning
algorithms of support vector machines (SVMs) and random
forests (RFs) along with the multivariate statistical technique of
partial least squares discriminant analysis (PLS-DA). Each
chromatogram contained approximately 8400 data points, i.e.
all of the features. This enables multivariate methods such as
PLS-DA to be able to detect “hidden features” that are crucial for
the model to distinguish between cancer and control samples,
which univariate methods are not able to identify properly.
It is clear to see that the C3 v TCC1 dataset has been the most
diﬃcult to classify due to the nature of the datasets: TCC1 being
the low grade and C3 other urological diseases. The random
forests and support vector machines algorithms have not per-
formed as well as the partial least squares discriminant analysis
algorithm in this instance. As far as the classication models
are concerned, the classiers were trained with the two most
disparate groups: control 1 (C1), representing healthy males or
females, and the TCC groups incorporating people suﬀering
from bladder cancer. Since group C1 possesses the most
diﬀerences compared to the cancer group, the classication
outcome of this sample set was expected to be the best. However
this was surprisingly not the case. A mean total accuracy of
87.5%, 89.0% and 80.9% were attained for PLS-DA, SVM and RF
respectively.
Next, the classier with control 2 (C2) and the cancer group
(TCC) data was trained. Urine samples within this control
subgroup showed similar abnormalities on dipstick analysis to
some cancer samples, such as blood, for example, and were
therefore more diﬃcult to distinguish from cancerous samples
than control 1 (C1) samples. However, the achieved specicity
contradicts this (for example, PLS-DA at 88.2% compared with
87.2% for C1). The overall classied accuracies attained were
greater for each classier than C1.
In the third experiment, the classier had to distinguish
between samples with conrmed non-cancerous urological
diseases (control 3) and cancerous samples (TCC). This was
expected to be the most diﬃcult combination, as disease
markers not specic to bladder cancer are likely to be present.
The achieved total accuracies appeared to perform better than
expected as they attained values of 83.0%, 83.5% and 83.6% for
PLS-DA, SVM and RF respectively. However it is noted that the
specicities attained were especially poor for SVM Lin and RF
(<50%) yet PLS-DA was at 66.1% suggesting that PLS-DA is the
better algorithm. The specicity values attained can be attrib-
uted to the unbalanced nature of the data since the TCC
subgroup is far greater (combining TCC1, TCC2 and TCC3) than
the C3 subgroup (Table 1) suggesting that the models learn
better the patterns attributed to the TCC groupmore so than the
C3 group.
The remaining experiments focusing on C3 versus the TCC
cancer grades (TCC1, TCC2 and TCC3) show that SVM-Lin was
better than PLS-DA and RF at discriminating the control (C3)
from the TCC grades due to the overall and sensitivities attained
for C3 v TCC2 and C3 v TCC3 (SVM > PLS-DA > RF). However, for
C3 v TCC1, PLS-DA was shown to be better than SVM and RF,
especially as the latter two only achieved sensitivities of 41.4%
and 54.0% respectively. This suggests that the PLS-DA classier
was able to distinguish to a certain extent the C3 control from
the low grade TCC (TCC1) whilst SVM and RF could not. From
a clinical perspective, the ability to distinguish between the C3
control and TCC1 is of paramount importance.
To assess the signicance of the presented results, permu-
tation testing via a Monte Carlo simulation was carried out.
Fig. 2 shows the results attained for each of the six experiments
each with 300 random runs (dark grey vertical bars) for the PLS-
DA classier. It also shows the respective distributions of the
observed analytical accuracies attained via the 150 classication
models generated (light grey vertical bars) during the analysis.
Although overlap had been observed in the distributions for
C3 v TCC and C3 v TCC1 (Fig. 2), the Z-test41 was carried out to
test for signicance between themeans of the two distributions.
As Table 3 shows, all calculated probability (p) values were lower
than the critical value (a ¼ 0.05) indicating that the means of
the two distributions are statistically signicantly diﬀerent.
This implies that the controls can be distinguished from TCC as
well as C3 against all of the TCC grades. Furthermore, the area
under the receiver operating characteristic (AUROC) curve
This journal is © The Royal Society of Chemistry 2016 Anal. Methods, 2016, 8, 4037–4046 | 4041
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values calculated for each of the experiments (Table 2) give
further support to the ndings with values ranging from 0.93 for
C2 v TCC to 0.74 for C3 v TCC1 for the PLS-DA classier.
Diagnostic potential
By combining gas chromatography mass spectrometry with
pattern recognition techniques, progress towards a new
instrumental method of bladder cancer detection based on
volatile biomarkers has been made. The obtained results
conrm that there is a clear relationship between the acquired
GC-MS data and the cancer status of the respective samples.
This relationship shows promise as the basis of a non-invasive
diagnostic technique. As many as 88.5% of cancer patients and
88.2% of non-cancerous subjects were correctly classied when
the classier was trained with a combination of TCC positive
urine samples and samples from healthy control groups con-
taining patients diagnosed with some form of non-cancerous
disease such as urinary tract infections (C2).
Samples from group C2 showed abnormalities such as
blood, for example haematuria – blood in the urine – is the most
common symptom of bladder cancer. Samples containing
traces of blood therefore represent a challenge for the distinc-
tion between control samples and bladder cancer samples.
However, the major contributor to this classication outcome
was control group 3. All subjects within this subgroup had
conrmed non-cancerous urological disease, the pathological
eﬀects of which are likely to be similar to the secondary eﬀects
of bladder cancer. Within both these groups, varying amounts
of metabolic products associated with inammation, infection
and/or necrosis will almost certainly be present. Because of this,
control 3 samples form the most important control subset and
contain the most relevant information. Training the classier
with this kind of data is therefore fundamental in order to be
able to subtract general disease compounds present in the urine
from those specic for bladder cancer. Accurate diagnosis of the
control subjects is, of course, paramount to this process, since
the inclusion of false negative individuals would lead to incor-
rect classication rules.
Interestingly, within the TCC sample group, the majority of
those incorrectly classied as negative were from patients with
more advanced tumours. In these cases, it is possible that
metabolic products generated secondarily to the tumour may
overwhelm or mask the volatile cancer biomarkers within the
urine, giving rise to a urine headspace more closely resembling
that of control 3 samples. Canine olfactory studies support this
hypothesis; high grade TCCs with a signicant level of invasion
are missed more frequently by trained dogs than low-grade
supercial tumours.42
Fig. 2 also showed the increase in complexity of the control
samples (C1 to C3) as reected in the poorer performing models
with overall classications of 80%, 80% and 73% for C1,
C2 and C3 respectively. In most cases, the best performing
models were shown to achieve an overall classication of 95%
for both C1 and C2, and 92% for C3. More so, Fig. 2 clearly
illustrates the diﬃculty in distinguishing the C3 control group
from the TCC1 cancer group via PLS-DA. This was also observed
via support vector machines (SVMs) and random forests (RFs)
suggesting that a more rigorous modelling algorithm/machine
learning technique is warranted in conjunction with data pre-
processing and pre-treatment methods.
Visualisation of the PLS-DA loadings revealed a number of
possible metabolites/compounds which could be potential
biomarkers for the determination of TCC. These are summar-
ised in Table 4. As is oen the case with complex samples
analysed by GC-MS, the identity of some compounds deter-
mined through using NIST (National Institute of Standards and
Technology) and MassBank (http://www.massbank.jp) is less
Table 2 Performances of machine learning algorithms. LV denotes the best number of latent variables (PLS-DA); tree denotes the optimum
number of trees for Random Forest (RF). Lin denotes Linear kernel for support vector machines (SVMs); TCC implies TCC1, TCC2 and TCC3
combined; AUROC is the area under the receiver operating characteristic curve
Dataset Model comparison % overall % spec % sens LV or tree AUROC
C1 v TCC PLS-DA 87.53 87.23 87.82 16 0.906
SVM Lin 88.99 88.84 89.13 — 0.935
RF 80.91 80.28 81.75 450 0.892
C2 v TCC PLS-DA 88.35 88.21 88.48 12 0.928
SVM Lin 89.18 88.00 90.33 — 0.922
RF 82.70 82.93 82.72 450 0.865
C3 v TCC PLS-DA 83.01 66.06 88.66 8 0.8680
SVM Lin 83.48 44.36 96.52 — 0.9023
RF 83.57 42.90 86.99 150 0.8427
C3 v TCC1 PLS-DA 69.18 66.18 73.29 13 0.7424
SVM Lin 67.30 86.15 41.38 — 0.6363
RF 67.33 77.63 54.03 450 0.7102
C3 v TCC2 PLS-DA 80.51 71.39 88.23 7 0.8985
SVM Lin 81.44 72.15 89.31 — 0.9040
RF 75.87 64.31 86.66 350 0.8642
C3 v TCC3 PLS-DA 79.70 73.48 85.17 20 0.8580
SVM Lin 81.46 73.91 88.11 — 0.9283
RF 74.44 66.76 81.64 350 0.8098
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certain due to incomplete separation and similar library spectra
for diﬀerent (but related) compounds. However, based on the
most likely compound identication, the list does not seem to
concur with the list of biomarkers suggested by Pasikanti et al.43
Yet some of the suggested compounds in Table 4 have been
identied as being signicant in colo-rectal cancer, i.e. 2-pen-
tanone, hexanal and 2,3-butanedione44 (suggested in Table 4 to
decrease from C3 to TCC); 3-hydroxyanthranilic acid has been
found in bladder cancer45 (suggested in Table 4 to increase from
C3 to TCC). In addition, 4-heptanone (suggested in Table 4 to
Fig. 2 Distribution of the overall percentage classiﬁed after randomised assignation of classes to the samples (dark grey vertical bars) corre-
sponding to each of the six experiments via the PLS-DA classiﬁer. Number of runs: 300. The light grey vertical bars denote distribution of the
observed accuracies attained via the classiﬁcation models (150 runs). It can be seen that the respective means of the accuracy attained (the
maxima of the rightmost distribution curve) is beyond two standard deviations of the respective permutation means (the maxima of the leftmost
distribution curve) indicating that statistically signiﬁcant results had been achieved at the 95% conﬁdence level. This is further corroborated in
Table 3. Conﬁdence intervals (CI) for evaluations: (C1 v TCC: mean: 87.5%; CI (95%): 82–94%); (C2 v TCC: mean: 88.4%; CI (95%): 82–95%); (C3 v
TCC: mean: 83.0%; CI (95%): 75–91%); (C3 v TCC1: mean: 69.2%; CI (95%): 54–84%); (C3 v TCC2: mean: 80.5%; CI (95%): 70–90%); (C3 v TCC3:
mean: 79.7%; CI (95%): 68–91%).
This journal is © The Royal Society of Chemistry 2016 Anal. Methods, 2016, 8, 4037–4046 | 4043
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decrease from C3 to TCC) was reported to be a marker for
bladder cancer when human urine was analysed via headspace
GC-MS.46 Other chemicals have been reported in the medical
literature, but not as cancer markers. For example, piperitone
has been reported to inhibit the cervical cancer cell-line
growths,47 benzoic acid (suggested in Table 4 to increase from
C3 to TCC) reduces bladder cancer when as a functional group
within the retinoid-related molecule AGN193198,48 and butyro-
phenone (suggested in Table 4 to increase from C3 to TCC) is
employed in the treatment of schizophrenia and other central
nervous disorders49 though it is unclear if any patients were
taking this medication.
It should be noted that some biomarkers are almost ubiq-
uitous biomarkers and can be seen as volatile compounds
emanating from biological systems; examples include: dimethyl
disulphide, 2-butanone, 2-propanol, acetic acid, etc. However,
their relative concentrations may alter due to the presence of
abnormal metabolism, and this may give information about
changes occurring in that system. Though use of an internal
standard had been employed (deuterated phenol), it may not
have accounted for diﬀering concentrations – where it had been
observed during sample preparation that some urine samples
were very watery whilst others more concentrated. However the
same volume of urine was always taken therefore it is possible
to make use of a naturally occurring internal standard such as
creatinine. Furthermore, the concentration of acetic acid in the
headspace may increase if the pH surrounding a tumour is
lowered because it pushes the chemical equilibrium away from
the acetate ion and to the acetic acid molecule which is much
more volatile and hence detectable by this method. For this
reason, it is quite reasonable that some “cancer biomarkers” are
in fact compounds found under non-cancerous circumstances,
but with varying relative concentrations; these can still form the
basis for a diagnostic test.
Although Pasikanti and colleagues claim 100% sensitivity in
identifying human bladder cancer,43 there is no specic
mention of identifying transitional cell carcinoma (TCC) in
conjunction with applying any retention time shi corrections.
The authors have also not specied the clinical diagnoses of any
of their controls (only that they had bladder cancer symptoms,
but were cystoscopy negative), so the nature, severity or chro-
nicity of their urological conditions are currently not known.
Though the article by Khalid et al.8 reported a success of 96%
accuracy using two alternative statistical approaches, the rst
involving a simple linear discriminant analysis on 9 selected
time points, and the second employing PLS-DA on all time
points, both approaches only employed leave-one-out cross-
validation. This has been shown to give overoptimistic results
and it is thus recommended to employ a more thorough vali-
dation approach employing cross-model validation and
permutation testing37 as has been employed in this work, and
thus permitting greater condence and reliability in the results
presented. Finally, recent work has been reported in which
nanoparticles are employed in conjunction with cystoscopy to
improve the recognition of tumours, for example distinguishing
at lesions from non-malignant cells, yet though outcomes are
positive, there is still an invasive element to the procedure.50
Finally, in a recent paper by Aggio et al., it was reported that
a GC-sensor was able to distinguish in urine prostate cancer
from controls, bladder cancer from controls, and bladder
cancer from prostate cancer via an in-house data processing
and analysis pipeline reporting very high ([90%) accuracies,
sensitivities and specicities.51 It was stated that “diﬀerent
VOCs are associated with the two urological disorders” however
it must be suggested that it is very likely that there will also be
the same VOCs present in both cancers. Both statements can be
corroborated via the use of mass spectrometry in order to
identify compounds, the potential of which have been demon-
strated in this work, and are acknowledged by the authors for
their future work.
Conclusions
PLS-DA-derived models gave a mean accuracy for patients pre-
senting with other non-cancerous urological disease of 88.4%,
with 88.5% sensitivity and 88.2% specicity for C2 versus TCC
(TCC1, TCC2 and TCC3 combined). SVM-derived models had
given a mean accuracy of 89.2%, with a sensitivity of 90.3% and
specicity of 88.0%. Although the specicities achieved were
Table 3 Determination of statistical signiﬁcance via the Z-test for the
overlapping distributions in Fig. 2 (permutation “null” models in dark
grey and observed classiﬁcation in light grey) for PLS-DA. Calculated
p-value is the probability at the 95% conﬁdence level (a ¼ 0.05)
Case
Overall accuracy
(%)
Z value
(Zcrit ¼ 1.96)
p-Value
(a ¼ 0.05)
Signicant
diﬀerence
C1 v TCC 87.53 143.61 <0.0001 Yes
C2 v TCC 88.35 147.54 <0.0001 Yes
C3 v TCC 83.01 32.02 <0.0001 Yes
C3 v TCC1 69.18 24.42 <0.0001 Yes
C3 v TCC2 80.51 66.07 <0.0001 Yes
C3 v TCC3 79.70 56.70 <0.0001 Yes
Table 4 A list of possible biomarkers identiﬁed from the PLS-DA
loadings in conjunction with the NIST and MassBank databases.
Change denotes the median value of abundance from control (C3) to
cancer (TCC)
Compound Database Change
2-Pentanone NIST & MassBank Decrease
2,3-Butanedione MassBank Decrease
4-Heptanone MassBank Decrease
Dimethyl disulphide NIST Decrease
Hexanal NIST Increase
Benzaldehyde MassBank Increase
Butyrophenone MassBank Increase
3-Hydroxyanthranilic acid MassBank Increase
Benzoic acid MassBank Increase
trans-3-Hexanoic acid MassBank Increase
cis-3-Hexanoic acid MassBank Increase
2-Butanone NIST Increase
2-Propanol NIST Decrease
Acetic acid NIST Decrease
Piperitone MassBank Decrease
Thujone MassBank Decrease
4044 | Anal. Methods, 2016, 8, 4037–4046 This journal is © The Royal Society of Chemistry 2016
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marginally less than that of conventional urine cytology (typi-
cally >90% specicity), sensitivity was very close to typical range
of 80–90% for high-grade tumours52 and thus better than the
typical range of 20–50% for low-grade tumours,3 case in point,
the sensitivity attained for C3 v TCC1 was 73.3% which is
considerably better than the “gold-standard” of 20–50%. Of
course, further improvement is still highly warranted.
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